Adeno-associated Virus (AAV) Vector-based Gene Therapy Market
Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Global Industry Assessment & Forecast
#
Pages:
220
Base Year:
2024
Nov - 2024
Format:
Report Code:
VMR-3397
Segments Covered
By
Disease Type Hematological Malignancies, Neurological Disorders, Cardiovascular Diseases, Ophthalmic Diseases, Oncology
-
By
Vector Serotype AAV1, AAV2, AAV5, AAV6, AAV8, AAV9
-
By
Administration Route Intravenous, Intramuscular, Subcutaneous, Intraocular, Intracerebral
-
By
End User Hospitals, Research Institutes, Biopharmaceutical Companies
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2024 |
| Forecast
Years:
|
2025 - 2034 |
 Historical
Years:
|
2019 - 2023 |
 Revenue
2024: |
USD 6.02 Billion |
 Revenue 2034:
|
USD 32.96 Billion |
 Revenue CAGR
(2025 - 2034): |
18.2% |
Fastest Growing Region (2025 -
2034)
|
North America |
Largest Region (2024):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Segment Analysis
- Adeno-associated Virus (AAV) Vector-based Gene Therapy Disease Type Outlook (Revenue, USD Million, 2018 - 2030)
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Adeno-associated Virus (AAV) Vector-based Gene Therapy Vector Serotype Outlook (Revenue, USD Million, 2018 - 2030)
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Adeno-associated Virus (AAV) Vector-based Gene Therapy Administration Route Outlook (Revenue, USD Million, 2018 - 2030)
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Adeno-associated Virus (AAV) Vector-based Gene Therapy End User Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
-
North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
-
North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
-
North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- U.S.
- U.S. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- U.S. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- U.S. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- U.S. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- U.S. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Canada
- Canada Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Canada Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Canada Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Canada Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Canada Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Mexico
- Mexico Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Mexico Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Mexico Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Mexico Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Mexico Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Europe
-
Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
-
Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
-
Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
-
Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- U. K.
- U.K. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- U.K. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- U.K. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- U.K. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- U.K. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- France
- France Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- France Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- France Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- France Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- France Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Germany
- Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Italy
- Italy Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Italy Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Italy Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Italy Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Italy Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Spain
- Spain Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Spain Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Spain Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Spain Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Spain Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Rest of Europe
- Rest of Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Rest of Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Rest of Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Rest of Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Rest of Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Asia Pacific
-
Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
-
Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
-
Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
-
Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- China
- China Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- China Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- China Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- China Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- China Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Japan
- Japan Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Japan Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Japan Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Japan Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Japan Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Germany
- Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
India
- India Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- India Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- India Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- India Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- India Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
South Korea
- South Korea Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- South Korea Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- South Korea Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- South Korea Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- South Korea Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
South East Asia
- South East Asia Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- South East Asia Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- South East Asia Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- South East Asia Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- South East Asia Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Rest of Asia Pacific
- Rest of Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Rest of Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Rest of Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Rest of Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Rest of Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Latin America
-
Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
-
Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
-
Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
-
Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Brazil
- Brazil Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Brazil Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Brazil Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Brazil Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Brazil Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Argentina
- Argentina Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Argentina Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Argentina Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Argentina Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Argentina Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Rest of Latin America
- Rest of Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Rest of Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Rest of Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Rest of Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Rest of Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Middle East & Africa
-
Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
-
Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
-
Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
-
Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- GCC Countries
- GCC Countries Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- GCC Countries Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- GCC Countries Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- GCC Countries Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- GCC Countries Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- South Africa
- South Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- South Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- South Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- South Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- South Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- Hematological Malignancies
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Oncology
- Rest of Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
- AAV1
- AAV2
- AAV5
- AAV6
- AAV8
- AAV9
- Rest of Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
- Intravenous
- Intramuscular
- Subcutaneous
- Intraocular
- Intracerebral
- Rest of Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
- Hospitals
- Research Institutes
- Biopharmaceutical Companies
- Rest of Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
-
Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
- North America
FAQ
Frequently Asked Question
What is the global demand for Adeno-associated Virus (AAV) Vector-based Gene Therapy in terms of revenue?
-
The global Adeno-associated Virus (AAV) Vector-based Gene Therapy valued at USD 6.02 Billion in 2024 and is expected to reach USD 32.96 Billion in 2034 growing at a CAGR of 18.2%.
Which are the prominent players in the market?
-
The prominent players in the market are Pfizer, BioMarin Pharmaceutical, Sarepta Therapeutics, Takeda, UniQure, Regenxbio, Adverum Biotechnologies, Spark Therapeutics (Roche), Astellas Pharma, Bayer, Ultragenyx Pharmaceutical, Audentes Therapeutics (Astellas), Homology Medicines, GenSight Biologics, Sangamo Therapeutics..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 18.2% between 2025 and 2034.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Adeno-associated Virus (AAV) Vector-based Gene Therapy include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Adeno-associated Virus (AAV) Vector-based Gene Therapy in 2024.
